Rashmi Agni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rashmi Agni has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Abdolreza Haririan
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
1 shared publication - Alexei Mikhailov
UNC Department of Pathology and Laboratory Medicine, Chapel Hill, North Carolina, USA; Atrium Health Wake Forest Baptist Medical Center Department of Pathology, Winston-Salem, North Carolina, USA
1 shared publication - Alton Brad Farris
Department of Pathology, Emory University, Atlanta, Georgia, USA
1 shared publication Anne O. Lidor
Department of Surgery, University of Wisconsin—Madison, Madison, Wisconsin, USA
1 shared publicationAnthony C. Gamst
Computational and Applied Statistical Laboratory (CASL), San Diego Supercomputer Center, University of California San Diego, San Diego, California, USA
1 shared publication- Autumn LaRocque
Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA
1 shared publication
Latest Publications
- Open Access
- 10 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (8) , 1787-1802
Banff 2024 Pancreas Transplantation Report: Diagnosis and impact of chronic active T cell-mediated allograft rejection and re-evaluation of the indeterminate category with utilization of leukocyte immunostains in biopsies with ambiguous findings
- 10 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (8) , 1787-1802
Open AccessBanff 2024 Pancreas Transplantation Report: Diagnosis and impact of chronic active T cell-mediated allograft rejection and re-evaluation of the indeterminate category with utilization of leukocyte immunostains in biopsies with ambiguous findings
- 25 March 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (1) , 127-141
Proton density fat fraction for diagnosis of metabolic dysfunction–associated steatotic liver disease
Background and Aims: Prior work has shown that MRI-derived proton density fat fraction (PDFF) can diagnose metabolic dysfunction-associated steatotic liver disease (MASLD) noninvasively, but there is a paucity of data on the performance of PDFF to classify more advanced forms of the MASLD spectrum. The purpose of this study was to assess the diagnostic performance of PDFF for the diagnoses of MASLD, metabolic dysfunction-associated steatohepatitis (MASH), and fibrotic MASH in adults with obesity undergoing bariatric surgery, using contemporaneous intraoperative liver biopsy as a reference. Approach and Results: PDFF was evaluated alone and with other potential classifiers (imaging, serum and anthropometric), using Bayesian Information Criterion-based stepwise logistic regression models. Areas under the receiver operating characteristic (ROC) curves (AUC) were computed for all models and single classifiers. Cross-validated sensitivity and specificity were calculated at Youden-based PDFF classification thresholds. Data analysis from 140 patients demonstrated that PDFF was the most accurate single classifier, with high AUC for MASLD (0.95), MASH (0.85), and fibrotic MASH (0.82) (all p <0.001). Multivariable models, including PDFF, outperformed those without PDFF. The Youden-based threshold for PDFF was 4.4% for MASLD (sensitivity: 87%, specificity: 86%), 6.9% for MASH (sensitivity: 77%, specificity: 66%), and 13.5% for fibrotic MASH (sensitivity: 67%, specificity: 85%). Conclusions: PDFF was the most accurate single classifier for diagnosing MASLD, MASH, and fibrotic MASH. The most accurate multivariable classification models for MASLD, MASH, and fibrotic MASH included PDFF, demonstrating the central importance of PDFF for noninvasive assessment of the MASLD spectrum.
- 25 March 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (1) , 127-141
Proton density fat fraction for diagnosis of metabolic dysfunction–associated steatotic liver disease
Background and Aims: Prior work has shown that MRI-derived proton density fat fraction (PDFF) can diagnose metabolic dysfunction-associated steatotic liver disease (MASLD) noninvasively, but there is a paucity of data on the performance of PDFF to classify more advanced forms of the MASLD spectrum. The purpose of this study was to assess the diagnostic performance of PDFF for the diagnoses of MASLD, metabolic dysfunction-associated steatohepatitis (MASH), and fibrotic MASH in adults with obesity undergoing bariatric surgery, using contemporaneous intraoperative liver biopsy as a reference. Approach and Results: PDFF was evaluated alone and with other potential classifiers (imaging, serum and anthropometric), using Bayesian Information Criterion-based stepwise logistic regression models. Areas under the receiver operating characteristic (ROC) curves (AUC) were computed for all models and single classifiers. Cross-validated sensitivity and specificity were calculated at Youden-based PDFF classification thresholds. Data analysis from 140 patients demonstrated that PDFF was the most accurate single classifier, with high AUC for MASLD (0.95), MASH (0.85), and fibrotic MASH (0.82) (all p <0.001). Multivariable models, including PDFF, outperformed those without PDFF. The Youden-based threshold for PDFF was 4.4% for MASLD (sensitivity: 87%, specificity: 86%), 6.9% for MASH (sensitivity: 77%, specificity: 66%), and 13.5% for fibrotic MASH (sensitivity: 67%, specificity: 85%). Conclusions: PDFF was the most accurate single classifier for diagnosing MASLD, MASH, and fibrotic MASH. The most accurate multivariable classification models for MASLD, MASH, and fibrotic MASH included PDFF, demonstrating the central importance of PDFF for noninvasive assessment of the MASLD spectrum.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Gastrointestinal Medicine
- Vol. 2025 (1) , 5519015
Endoscopic Ultrasound With Fine Needle Biopsy Confirming a Diagnosis of Immune Checkpoint Inhibitor‐Related Type 3 Autoimmune Pancreatitis
Introduction: Immune checkpoint inhibitor‐related pancreatitis, also known as type 3 autoimmune pancreatitis (AIP), is uncommon and has a widely ranging clinical presentation. We present the biopsy findings of a case consistent with type 3 AIP—an entity recently described in the literature, the pathologic findings of which have not been well characterized. Case Report: A 71‐year‐old male with metastatic mucosal melanoma of the urethra was treated with immune checkpoint inhibitor (ICI) therapy (nivolumab/relatlimab) and developed vague epigastric discomfort. He was found to have an elevated lipase, which increased to > 20x the upper limit of normal. Subsequent imaging showed new infiltrative masses in the pancreatic head and distal body/tail. Endoscopic ultrasound with fine needle biopsy (FNB) was performed. This showed T‐lymphocyte predominant infiltrates, in the acini and septal areas, with concomitant acinar, duct, and venular damage, including both CD4 and CD8 lymphocytes, which were considered consistent with type 3 AIP. He was treated successfully with prednisone. Discussion: On biopsy, there was no evidence of malignancy or features of type 1 or type 2 AIP. Histologic findings included moderate infiltration and damage to the pancreatic parenchyma, ductal, and vascular structures by CD4 and CD8 lymphocytes, pointing to immune‐mediated pancreatic injury, and supportive of ICI‐mediated injury to the pancreas of this patient. The clinical presentation of type 3 AIP ranges from asymptomatic lipase elevation to asymptomatic pancreatitis to acute symptomatic pancreatitis. There may be no clear temporal relationship to treatment initiation. Type 3 AIP typically presents along with other immune‐related adverse events. Endoscopic ultrasound with FNB contributed to diagnostic certainty in this case and changed our patient’s management, allowing for appropriate treatment of his immune‐related adverse event.
- 1 January 2025
- Published by Wiley in Case Reports in Gastrointestinal Medicine
- Vol. 2025 (1) , 5519015
Open AccessEndoscopic Ultrasound With Fine Needle Biopsy Confirming a Diagnosis of Immune Checkpoint Inhibitor‐Related Type 3 Autoimmune Pancreatitis
Introduction: Immune checkpoint inhibitor‐related pancreatitis, also known as type 3 autoimmune pancreatitis (AIP), is uncommon and has a widely ranging clinical presentation. We present the biopsy findings of a case consistent with type 3 AIP—an entity recently described in the literature, the pathologic findings of which have not been well characterized. Case Report: A 71‐year‐old male with metastatic mucosal melanoma of the urethra was treated with immune checkpoint inhibitor (ICI) therapy (nivolumab/relatlimab) and developed vague epigastric discomfort. He was found to have an elevated lipase, which increased to > 20x the upper limit of normal. Subsequent imaging showed new infiltrative masses in the pancreatic head and distal body/tail. Endoscopic ultrasound with fine needle biopsy (FNB) was performed. This showed T‐lymphocyte predominant infiltrates, in the acini and septal areas, with concomitant acinar, duct, and venular damage, including both CD4 and CD8 lymphocytes, which were considered consistent with type 3 AIP. He was treated successfully with prednisone. Discussion: On biopsy, there was no evidence of malignancy or features of type 1 or type 2 AIP. Histologic findings included moderate infiltration and damage to the pancreatic parenchyma, ductal, and vascular structures by CD4 and CD8 lymphocytes, pointing to immune‐mediated pancreatic injury, and supportive of ICI‐mediated injury to the pancreas of this patient. The clinical presentation of type 3 AIP ranges from asymptomatic lipase elevation to asymptomatic pancreatitis to acute symptomatic pancreatitis. There may be no clear temporal relationship to treatment initiation. Type 3 AIP typically presents along with other immune‐related adverse events. Endoscopic ultrasound with FNB contributed to diagnostic certainty in this case and changed our patient’s management, allowing for appropriate treatment of his immune‐related adverse event.
- Open Access
- 24 May 2024
- Published by Hindawi Limited in Case Reports in Hepatology
- Vol. 2024, 1-4
Cholestasis Linked to Bodybuilding Supplements: Exploring the Risks of Contamination
Drug-induced liver injury resulting from herbal and dietary supplement use is increasingly common and underrecognized. We report a case of a 34-year-old male recreational bodybuilder who presented with muscle cramping, fatigue, and diffuse itching in the setting of bodybuilding supplement use. Labs showed cholestatic liver injury, and liver biopsy revealed bland cholestasis and sinusoidal dilation. He was diagnosed with anabolic-androgenic steroid-induced liver injury. He was symptomatically managed with plasmapheresis for debilitating pruritus. This case highlights drug-induced liver injury as a complication of bodybuilding supplement use containing unlabeled anabolic-androgenic steroids. Sports medicine providers should inquire on herbal and dietary supplement use and be aware of potential contaminants.
- 24 May 2024
- Published by Hindawi Limited in Case Reports in Hepatology
- Vol. 2024, 1-4
Open AccessCholestasis Linked to Bodybuilding Supplements: Exploring the Risks of Contamination
Drug-induced liver injury resulting from herbal and dietary supplement use is increasingly common and underrecognized. We report a case of a 34-year-old male recreational bodybuilder who presented with muscle cramping, fatigue, and diffuse itching in the setting of bodybuilding supplement use. Labs showed cholestatic liver injury, and liver biopsy revealed bland cholestasis and sinusoidal dilation. He was diagnosed with anabolic-androgenic steroid-induced liver injury. He was symptomatically managed with plasmapheresis for debilitating pruritus. This case highlights drug-induced liver injury as a complication of bodybuilding supplement use containing unlabeled anabolic-androgenic steroids. Sports medicine providers should inquire on herbal and dietary supplement use and be aware of potential contaminants.